Diagnosing and managing infectious esophagitis in immunocompromised patients

Infectious esophagitis is a common and potentially serious complication in patients undergoing chemotherapy, solid organ transplantation, or long-term immunosuppression for autoimmune disease. In immunocompromised hosts, pathogens such as Candida, herpes simplex virus, and cytomegalovirus can invade oesophageal mucosa, producing pain, dysphagia, and weight loss that often delay essential cancer treatment or transplant recovery. Prompt recognition and tailored therapy are central to restoring swallowing function and preventing systemic spread. Learn more about 運動時の呼吸循環応答と筋代謝需給バランスの評価.

This article walks through the practical approach used in Australian tertiary centres, from bedside assessment through endoscopy, microbiology, antifungal and antiviral prescribing, and post-treatment recovery planning. Local prescribing pathways under the Pharmaceutical Benefits Scheme and the reach of telehealth across rural and remote Australia are considered alongside the core clinical steps.

Recognising risk profiles and warning signs

Patients with haematological malignancy, those receiving high-dose corticosteroids, and recipients of allogeneic stem cell transplants face the highest risk of opportunistic oesophageal infection. HIV infection, advanced age, and poorly controlled diabetes add further vulnerability. In Australia, the typical case often presents during induction chemotherapy for acute myeloid leukaemia at a centre such as Royal Prince Alfred Hospital, or following a renal transplant at Westmead, where antifungal prophylaxis is routine but breakthrough infection still occurs.

The classic clinical picture is odynophagia and dysphagia, sometimes accompanied by retrosternal pain, nausea, and a low-grade fever. Oropharyngeal thrush is visible in roughly half of patients with candidal disease, but its absence does not rule out oesophageal extension. Where patients present remotely via telehealth from the Kimberley or outback Queensland, clinicians rely heavily on symptom reporting, recent treatment history, and expedited transfer to a tertiary endoscopy suite when alarm features emerge.

The role of endoscopy and tissue sampling

Upper endoscopy remains the diagnostic standard in symptomatic immunocompromised patients, allowing direct visualisation of plaques, ulcers, or diffuse inflammation, and providing biopsies for histopathology. Brushings alone miss viral inclusions, so multiple biopsies from the ulcer margin and base are recommended. Australian guidelines from the Gastroenterological Society of Australia align with international practice in recommending endoscopy before empirical therapy in patients with severe symptoms, weight loss, or refractory disease.

At high-volume centres such as Peter MacCallum Cancer Centre, endoscopic ultrasound is occasionally used to assess submucosal involvement in CMV disease. Where endoscopy is not feasible within a useful window, barium studies can identify mucosal irregularity but cannot identify the causative organism. Coordination with on-call endoscopy nursing staff and timely histopathology turnaround underpins a confident diagnosis.

Identifying the causative organism

Tissue biopsies should be sent for fungal staining, viral immunohistochemistry, and PCR where available. Candida species are identified on Grocott or PAS stain; HSV shows characteristic Cowdry A inclusions and margination of chromatin; CMV is recognised by large cells with intranuclear and intracytoplasmic inclusions, often confirmed by immunohistochemistry. Empirical treatment without tissue diagnosis risks missing polymicrobial infection, particularly in transplant recipients.

In Australian laboratories, PCR for CMV and HSV has largely replaced viral culture because of faster turnaround and higher sensitivity. Antifungal susceptibility testing is reserved for azole-resistant Candida or refractory disease, with the Alfred Hospital's mycology reference laboratory supporting statewide testing when needed. Blood CMV PCR is also drawn to gauge systemic involvement and inform antiviral dosing.

First-line antifungal therapy

For suspected or confirmed candidal oesophagitis, fluconazole 200 to 400 mg daily for two to three weeks remains the standard first line in patients tolerating oral therapy. In chemotherapy-induced neutropenia or azole-resistant Candida, intravenous caspofungin or anidulafungin is preferred. The PBS subsidises fluconazole and the echinocandins under specific criteria, which streamlines inpatient-to-community transitions across public hospitals.

Therapeutic Guidelines provide clear dosing guidance. Where oral intake is impossible, intravenous fluconazole or an echinocandin bridges initiation and ongoing therapy. Drug interactions are common, particularly with calcineurin inhibitors in transplant recipients, and tacrolimus or cyclosporin levels require close monitoring through outpatient transplant pharmacy.

Viral causes and antimicrobial choices

HSV oesophagitis is treated with aciclovir 400 mg five times daily, or valaciclovir 1 g three times daily, for seven to ten days. CMV oesophagitis requires ganciclovir 5 mg/kg twice daily induction for three to four weeks, followed by valganciclovir maintenance, with the PBS subsidising valganciclovir under specialist prescribing. Foscarnet is reserved for ganciclovir-resistant CMV, a scenario managed through infectious diseases consultation at tertiary centres.

Refractory cases warrant repeat endoscopy to exclude co-infection or alternative diagnoses such as pill oesophagitis, graft-versus-host disease, or malignancy. Acid-suppressive therapy should be reviewed, as proton pump inhibitors independently predispose to candidal infection. Liaison with infectious diseases, gastroenterology, and the patient's transplant or oncology team ensures antimicrobial choices align with the broader treatment plan.

Nutritional support and recovery planning

Weight loss, odynophagia, and mucositis frequently converge in these patients, and dietetic input should be sought early. Soft, energy-dense foods, oral nutritional supplements, and nasogastric feeding are options used across Australian hospitals, with percutaneous endoscopic gastrostomy considered for prolonged courses. Dietitians at the Royal Brisbane and Women's Hospital routinely integrate oral care bundles, antifungal mouthwashes, and pain control into nutritional counselling.

Rehabilitation planning is increasingly recognised, with assessments of functional capacity forming part of recovery. Physiotherapy-led evaluation of physiological reserve during recovery can draw on work such as cardiopulmonary response studies to frame exercise prescription safely for deconditioned patients. Successful return to oncological treatment, transplantation, or baseline activities depends on coordinated follow-up, repeat endoscopy where symptoms recur, and clear advice about when to seek urgent review.

The practical takeaway is that a structured pathway of risk recognition, early endoscopy with biopsies, targeted microbiology, PBS-supported antifungal or antiviral therapy, and integrated nutritional and rehabilitative care offers immunocompromised Australian patients the best chance of swift recovery from infectious esophagitis.